Trovagene's News Is Encouraging
Trovagene (TROV) is still a clinical-stage company. The precision cancer medicine approach is practicing what it preaches right now in order to develop drugs that target cell division (mitosis) for: leukemias, lymphomas and solid tumor cancers.
In March 2017, Trovagene licensed global development and commercialization rights for Onvansertib (PCM-075); a Polo-like Kinase 1 (PLK1) Inhibitor from Nerviano Medical Sciences; the largest research and development company in Italy and a leader in protein kinase . . .